Ironburg Inventions Ltd. v. Valve Corp., Appeal No. 2024-2088 (Fed. Cir. June 18, 2026)
Contributed by Schwabe Williamson & Wyatt. Originally published on Patexia; republished here as part of the LexDana archive.
CASE OF THE WEEK
Ironburg Inventions Ltd. v. Valve Corp., Appeal No. 2024-2088 (Fed. Cir. June 18, 2026)
In its only precedential patent opinion last week, the Federal Circuit for the second time considered estoppel under 35 U.S.C. § 315(e) in the context of infringement claims against videogame controllers provided by Valve Corporation. Section 315(e) prohibits a petitioner in a completed inter partes review from later asserting any grounds for invalidity “that the petitioner raised or reasonably could have raised during that inter partes review.” In a previous appeal in this case in 2023 (our write up here), the Federal Circuit held for the first time that the standard to be applied for the “reasonably could have raised” inquiry is whether “a skilled searcher conducting a diligent search reasonably could have been expected to discover” the grounds to be estopped. In the instant appeal following remand, the Federal Circuit provided further guidance on application of that “skilled searcher” standard, reversing the district court’s conclusion that Valve’s relevant invalidity arguments were estopped.
Editors:
Jason A. Wrubleski, Shareholder
Nika Aldrich, IP Litigation Group Leader, Schwabe
Contributor: Jason Wrubleski
More insights
Fresh From the Bench: Latest Precedential Patent Case
Ridge Corp. et al. v. Kirk NationaLease Co. et al. , Appeal No. 2025-1254 (Fed. Cir. July 13, 2026) In its only precedential patent opinion last week, the Federal Circuit considered an appeal of a preliminary injunction issued by the U.S. District Court…
Fresh From the Bench: Latest Precedential Patent Cases
CASE OF THE WEEK Wyeth LLC v. AstraZeneca Pharmaceuticals LP , Appeal No. 2024-2325 (Fed. Cir. July 9, 2026) In our Case of the Week, the Federal Circuit affirmed a district court ruling reversing a $107.5 million jury verdict against AstraZeneca in a case…
Enanta Pharmaceuticals, Inc. v. Pfizer Inc., Appeal No. 2025-1427 (Fed. Cir. Jun. 23, 2026)
CASE OF THE WEEK Enanta Pharmaceuticals, Inc. v. Pfizer Inc., Appeal No. 2025-1427 (Fed. Cir. Jun. 23, 2026) In our Case of the Week, the Federal Circuit affirmed summary judgment invalidating all claims of Enanta’s Patent No. 11,358,953 as…